OpenLB
Open Library of Bioscience
Advanced Search
CNS & neurological disorders drug targets
2024;23 (9): 1120-1133.

Anti-seizure Medications: Challenges and Opportunities.

Neha Tandon, Milica Radosavljevic, Danijela Vucevic, Miroslav Radenkovic, Jasna Jancic, Janko Samardzic
Author Information
  1. Neha Tandon: Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  2. Milica Radosavljevic: Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  3. Danijela Vucevic: Institute of Pathophysiology, "Ljubodrag Buba Mihailović", Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  4. Miroslav Radenkovic: Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  5. Jasna Jancic: Clinic of Neurology and Psychiatry for Children and Youth, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  6. Janko Samardzic: Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ORCID
PMID: 38192128 DOI: 10.2174/0118715273275793231030060833

Abstract

Epilepsy is a chronic neurological condition characterized by unprovoked, recurrent seizures. There are several types of epilepsy, and the cause of the condition can vary. Some cases of epilepsy have a genetic component, while others may be caused by brain injuries, infections, or other underlying conditions. Treatment for epilepsy typically involves anti-seizure medications (ASMs), although different approaches, such as surgery or a special diet, may be considered in specific cases. The treatment aims to effectively manage and potentially eliminate seizures while minimizing any accompanying side effects. Many different ASMs are available, and the choice of medication depends on several factors, including the type of seizures, the patient's age, general health, and potential drug interactions. For the treatment of epilepsy, there have been significant advancements in recent decades, which have led to the approval of many different ASMs. Newer ASMs offer a broader range of mechanisms of action, improved tolerability profiles, and reduced drug interactions compared to older drugs. This review aims to discuss the pharmacological characteristics, clinical applications, effectiveness, and safety of ASMs, with a particular emphasis on various age groups, especially children. Moreover, this review seeks to provide a comprehensive understanding of ASM therapy for epilepsy management, assisting physicians in selecting suitable ASMs for their patients.

Keywords

Epilepsy anti-seizure medications neuropharmacology. pharmacotherapy precision medicine seizures

References

  1. Maxwell S.R.J.; Rational prescribing: The principles of drug selection. Clin Med 2016,16(5),459-464 [DOI: 10.7861/clinmedicine.16-5-459]
  2. Mathur S.; Sutton J.; Personalized medicine could transform healthcare. Biomed Rep 2017,7(1),3-5 [DOI: 10.3892/br.2017.922]
  3. St Louis E.K.; Rosenfeld W.E.; Bramley T.; Antiepileptic drug monotherapy: The initial approach in epilepsy management. Curr Neuropharmacol 2009,7(2),77-82 [DOI: 10.2174/157015909788848866]
  4. Kim K.T.; Kim D.W.; Yang K.I.; Refining general principles of antiepileptic drug treatments for epilepsy. J Clin Neurol 2020,16(3),383-389 [DOI: 10.3988/jcn.2020.16.3.383]
  5. Camfield P.; Camfield C.; Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord 2015,17(2),117-123 [DOI: 10.1684/epd.2015.0736]
  6. Sarmast S.T.; Abdullahi A.M.; Jahan N.; Current classification of seizures and epilepsies: Scope, limitations and recommendations for future action. Cureus 2020,12(9),e10549 [DOI: 10.7759/cureus.10549]
  7. Anwar H.; Khan Q.U.; Nadeem N.; Pervaiz I.; Ali M.; Cheema F.F.; Epileptic seizures. Discoveries 2020,8(2),e110 [DOI: 10.15190/d.2020.7]
  8. Singh A.; Trevick S.; The epidemiology of global epilepsy. Neurol Clin 2016,34(4),837-847 [DOI: 10.1016/j.ncl.2016.06.015]
  9. Manole A.; Sirbu C.; Mititelu M.; State of the art and challenges in epilepsy—a narrative review. J Pers Med 2023,13(4),623 [DOI: 10.3390/jpm13040623]
  10. Bell G.S.; Sander J.W.; CPD — Education and self-assessment The epidemiology of epilepsy: The size of the problem. Seizure 2001,10(4),306-316 [DOI: 10.1053/seiz.2001.0584]
  11. Begley C.; Wagner R.G.; Abraham A.; The global cost of epilepsy: A systematic review and extrapolation. Epilepsia 2022,63(4),892-903 [DOI: 10.1111/epi.17165]
  12. Eadie M.J.; Potassium bromide and Sir Charles Locock. J R Coll Physicians Edinb 2012,42,274-279 [DOI: 10.4997/JRCPE.2012.317]
  13. Shorvon S.D.; Drug treatment of epilepsy in the century of the ILAE: The first 50 years, 1909–1958. Epilepsia 2009,50(S3),69-92 [DOI: 10.1111/j.1528-1167.2009.02041.x]
  14. Shorvon S.D.; Drug treatment of epilepsy in the century of the ILAE: The second 50 years, 1959–2009. Epilepsia 2009,50(s3)(Suppl. 3),93-130 [DOI: 10.1111/j.1528-1167.2009.02042.x]
  15. Bialer M.; Johannessen S.I.; Koepp M.J.; Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia 2022,63(11),2883-2910 [DOI: 10.1111/epi.17376]
  16. electronic medicines compendium. Available from: https://www.medicines.org.uk/emc2021
  17. Johannessen Landmark C.; Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy. CNS Drugs 2008,22(1),27-47 [DOI: 10.2165/00023210-200822010-00003]
  18. Li C.; Xue L.; Liu Y.; Yang Z.; Chi S.; Xie A.; Zonisamide for the treatment of Parkinson disease: A current update. Front Neurosci 2020,14,574652 [DOI: 10.3389/fnins.2020.574652]
  19. Fisher R.S.; Boas W.E.; Blume W.; Epileptic seizures and epilepsy: Definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia 2005,46(4),470-472 [DOI: 10.1111/j.0013-9580.2005.66104.x]
  20. Fisher R.S.; Acevedo C.; Arzimanoglou A.; ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014,55(4),475-482 [DOI: 10.1111/epi.12550]
  21. Nevitt S.J.; Sudell M.; Cividini S.; Marson A.G.; Tudur Smith C.; Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data. Cochrane Database Syst Rev 2022,4(4),CD011412 [PMID: 35363878]
  22. French J.A.; Gazzola D.M.; New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf 2011,2(4),141-158 [DOI: 10.1177/2042098611411127]
  23. Ferrari M.D.; Goadsby P.J.; Burstein R.; Migraine. Nat Rev Dis Primers 2022,8(1),2 [DOI: 10.1038/s41572-021-00328-4]
  24. Stovner L.J.; Hagen K.; Linde M.; Steiner T.J.; The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 2022,23(1),34 [DOI: 10.1186/s10194-022-01402-2]
  25. Szperka C.; Headache in Children and Adolescents. Continuum 2021,27(3),703-731 [DOI: 10.1212/CON.0000000000000993]
  26. Silberstein S.D.; Preventive migraine treatment. Neurol Clin 2009,27(2),429-443 [DOI: 10.1016/j.ncl.2008.11.007]
  27. Jia G.; Wang X.; Lv H.; The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials. Transl Pediatr 2021,10(7),1779-1791 [DOI: 10.21037/tp-20-478]
  28. Jain A.; Mitra P.; Bipolar Disorder 2023
  29. Cichoń L.; Janas-Kozik M.; Siwiec A.; Rybakowski J.; Clinical picture and treatment of bipolar affective disorder in children and adolescents. Psychiatr Pol 2020,54(1),35-50 [DOI: 10.12740/PP/OnlineFirst/92740]
  30. Ferensztajn-Rochowiak E.; Rybakowski J.K.; Long-term lithium therapy: Side Effects and Interactions. Pharmaceuticals 2023,16(1),74 [DOI: 10.3390/ph16010074]
  31. Crapanzano C.; Casolaro I.; Amendola C.; Damiani S.; Lithium and valproate in bipolar disorder: from international evidence-based guidelines to clinical predictors. Clin Psychopharmacol Neurosci 2022,20(3),403-414 [DOI: 10.9758/cpn.2022.20.3.403]
  32. Hashimoto Y.; Kotake K.; Watanabe N.; Fujiwara T.; Sakamoto S.; Lamotrigine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2021,9(9),CD013575 [PMID: 34523118]
  33. Findling R.L.; Chang K.; Robb A.; Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: A placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015,54(12),1020-1031.e3 [DOI: 10.1016/j.jaac.2015.09.017]
  34. Suppes T.; Marangell L.B.; Bernstein I.H.; A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008,111(2-3),334-343 [DOI: 10.1016/j.jad.2008.02.004]
  35. Szuhany K.L.; Simon N.M.; Anxiety Disorders. JAMA 2022,328(24),2431-2445 [DOI: 10.1001/jama.2022.22744]
  36. Baldwin D.S.; den Boer J.A.; Lyndon G.; Emir B.; Schweizer E.; Haswell H.; Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol 2015,29(10),1047-1060 [DOI: 10.1177/0269881115598411]
  37. Desmarais P.; Miville C.; Milán-Tomás Á.; Age representation in antiepileptic drug trials: A systematic review and meta-analysis. Epilepsy Res 2018,142,9-15 [DOI: 10.1016/j.eplepsyres.2018.03.005]
  38. Pellock J.M.; Carman W.J.; Thyagarajan V.; Daniels T.; Morris D.L.; D’Cruz O.; Efficacy of antiepileptic drugs in adults predicts efficacy in children: A systematic review. Neurology 2012,79(14),1482-1489 [DOI: 10.1212/WNL.0b013e31826d5ec0]
  39. Allen H.C.; Garbe M.C.; Lees J.; Off-label medication use in children, more common than we think: A systematic review of the literature. J Okla State Med Assoc 2018,111(8),776-783 [PMID: 31379392]
  40. Wadsworth I.; Jaki T.; Sills G.J.; Clinical drug development in epilepsy revisited: A proposal for a new paradigm streamlined using extrapolation. CNS Drugs 2016,30(11),1011-1017 [DOI: 10.1007/s40263-016-0383-y]
  41. Rohracher A.; Kalss G.; Kuchukhidze G.; New anti-seizure medication for elderly epilepsy patients - a critical narrative review. Expert Opin Pharmacother 2021,22(5),621-634 [DOI: 10.1080/14656566.2020.1843636]
  42. Morrell M.J.; The new antiepileptic drugs and women: Efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1996,37(S6),S34-S44 [DOI: 10.1111/j.1528-1157.1996.tb06037.x]
  43. Gil-Nagel A.; Elger C.; Ben-Menachem E.; Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013,54(1),98-107 [DOI: 10.1111/j.1528-1167.2012.03605.x]
  44. Kishk N.; Mourad H.; Ibrahim S.; Shamloul R.; Al-Azazi A.; Shalaby N.; Sex differences among epileptic patients: a comparison of epilepsy and its impacts on demographic features, clinical characteristics, and management patterns in a tertiary care hospital in Egypt. Egypt J Neurol Psychiat Neurosurg 2019,55(1),39 [DOI: 10.1186/s41983-019-0078-7]
  45. Reddy D.S.; Thompson W.; Calderara G.; Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett 2021,750,135753 [DOI: 10.1016/j.neulet.2021.135753]
  46. Velíšková J.; DeSantis K.A.; Sex and hormonal influences on seizures and epilepsy. Horm Behav 2013,63(2),267-277 [DOI: 10.1016/j.yhbeh.2012.03.018]
  47. Luef G.; Taubøll E.; Gender issues in epilepsy – Difference in management of epilepsy. Seizure 2015,28,1-2 [DOI: 10.1016/j.seizure.2015.02.001]
  48. Szaflarski M.; Szaflarski J.P.; Privitera M.D.; Ficker D.M.; Horner R.D.; Racial/ethnic disparities in the treatment of epilepsy: What do we know? What do we need to know? Epilepsy Behav 2006,9(2),243-264 [DOI: 10.1016/j.yebeh.2006.05.011]
  49. Kumar N; Aebi M; Lu E; Burant C; Sajatovic M; Ethnicity and health outcomes among people with epilepsy participating in an epilepsy self-management RCT. Epilepsy Behav 2019,101(Pt A),106469 [DOI: 10.1016/j.yebeh.2019.106469]
  50. Yu Z.; Dong K.; Chang H.; The epidemiological and clinical characteristics study on epilepsy in 8 ethnic groups of China. Epilepsy Res 2017,138,110-115 [DOI: 10.1016/j.eplepsyres.2017.10.020]
  51. Lim K.S.; Ng C.C.; Chan C.K.; Foo W.S.; Low J.S.Y.; Tan C.T.; Ethnic variation of genetic (idiopathic) generalized epilepsy in Malaysia. Seizure 2017,45,24-27 [DOI: 10.1016/j.seizure.2016.11.011]
  52. Gregerson C.H.Y.; Bakian A.V.; Wilkes J.; Disparities in pediatric epilepsy remission are associated with race and ethnicity. J Child Neurol 2019,34(14),928-936 [DOI: 10.1177/0883073819866623]
  53. QuickStats: Age-Adjusted Percentages* of Adults Aged ≥18 Years Who Have Epilepsy, by Epilepsy Status† and Race/Ethnicity§- National Health Interview Survey, United States, 2010 and 2013 Combined¶. MMWR Morb Mortal Wkly Rep https://www.cdc.gov/mmwr/volumes/65/wr/mm6523a8.htm2016,65(23),611 [DOI: 10.15585/mmwr.mm6523a8]
  54. Urzì Brancati V.; Pinto Vraca T.; Minutoli L.; Pallio G.; Polymorphisms Affecting the Response to Novel Antiepileptic Drugs. Int J Mol Sci 2023,24(3),2535 [DOI: 10.3390/ijms24032535]
  55. Parker D.; Sanders E.J.; Burghardt K.J.; Pharmacogenetics of antiepileptic drugs: A brief review. Ment Health Clin 2016,6(1),28-34 [DOI: 10.9740/mhc.2016.01.028]
  56. Balestrini S.; Sisodiya S.M.; Pharmacogenomics in epilepsy. Neurosci Lett 2018,667,27-39 [DOI: 10.1016/j.neulet.2017.01.014]
  57. Macdonald R.L.; Kelly K.M.; Antiepileptic drug mechanisms of action. Epilepsia 1995,36(s2)(Suppl. 2),S2-S12 [DOI: 10.1111/j.1528-1157.1995.tb05996.x]
  58. Brodie M.J.; Sodium channel blockers in the treatment of epilepsy. CNS Drugs 2017,31(7),527-534 [DOI: 10.1007/s40263-017-0441-0]
  59. Rajakulendran S.; Hanna M.G.; The role of calcium channels in epilepsy. Cold Spring Harb Perspect Med 2016,6(1),a022723 [DOI: 10.1101/cshperspect.a022723]
  60. Czuczwar S.J.; Patsalos P.N.; The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001,15(5),339-350 [DOI: 10.2165/00023210-200115050-00001]
  61. Subbarao B.S.; Silverman A.; Eapen B.C.; Seizure Medications 2022
  62. Hanada T.; Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors. Biomolecules 2020,10(3),464 [DOI: 10.3390/biom10030464]
  63. Hanrahan B.; Carson R.P.; Felbamate 2021
  64. Fariba K.; Saadabadi A.; Topiramate 2022
  65. Fukuyama K.; Okada M.; Brivaracetam and levetiracetam suppress astroglial l-glutamate release through hemichannel via inhibition of synaptic vesicle protein. Int J Mol Sci 2022,23(9),4473 [DOI: 10.3390/ijms23094473]
  66. Stafstrom C.E.; Mechanisms of action of antiepileptic drugs: The search for synergy. Curr Opin Neurol 2010,23(2),157-163 [DOI: 10.1097/WCO.0b013e32833735b5]
  67. Cloyd J.C.; Remmel R.P.; Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy. Pharmacotherapy 2000,20(8 Part 2),139S-151S [DOI: 10.1592/phco.20.12.139S.35255]
  68. Ha C.; Lee H.S.; Joo E.Y.; Levetiracetam therapeutic drug monitoring in a large cohort of Korean epileptic patients. Pharmaceuticals 2021,14(8),826 [DOI: 10.3390/ph14080826]
  69. Steinhoff B.J.; Staack A.M.; Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord 2019,12 [DOI: 10.1177/1756286419873518]
  70. Couderc S.; Chouchane M.; Saint-Marcoux F.; What is the therapeutic reference range for levetiracetam? grand round/a case study. Ther Drug Monit 2022,44(3),363-365 [DOI: 10.1097/FTD.0000000000000972]
  71. Shi M.; Liu C.; He L.; Wu H.; Wu Y.; Therapeutic drug monitoring and the therapeutic reference range of levetiracetam for Chinese patients: Problems and issues. Seizure 2023,109,26-33 [DOI: 10.1016/j.seizure.2023.05.010]
  72. Tolou-Ghamari Z.; Zare M.; Habibabadi J.M.; Najafi M.R.; A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci 2013,18(Suppl. 1),S81-S85 [PMID: 23961295]
  73. Marino S.E.; Birnbaum A.K.; Leppik I.E.; Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: Effects of race and sex. Clin Pharmacol Ther 2012,91(3),483-488 [DOI: 10.1038/clpt.2011.251]
  74. Greenberg R.G.; Melloni C.; Wu H.; Therapeutic index estimation of antiepileptic drugs: A systematic literature review approach. Clin Neuropharmacol 2016,39(5),232-240 [DOI: 10.1097/WNF.0000000000000172]
  75. Al Khalili Y.; Sekhon S.; Jain S.; Carbamazepine Toxicity. In: StatPearls 2022
  76. Lee S.K.; Old versus new: Why do we need new antiepileptic drugs? J Epilepsy Res 2014,4(2),39-44 [DOI: 10.14581/jer.14010]
  77. Hanaya R.; Arita K.; The new antiepileptic drugs: Their neuropharmacology and clinical indications. Neurol Med Chir 2016,56(5),205-220 [DOI: 10.2176/nmc.ra.2015-0344]
  78. Suresh S.H.; Chakraborty A.; Virupakshaiah A.; Kumar N.; Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. Epilepsy Res Treat 2015,2015,1-6 [DOI: 10.1155/2015/415082]
  79. Beydoun A.; DuPont S.; Zhou D.; Matta M.; Nagire V.; Lagae L.; Current role of carbamazepine and oxcarbazepine in the management of epilepsy. Seizure 2020,83,251-263 [DOI: 10.1016/j.seizure.2020.10.018]
  80. Georgoff P.E.; Nikolian V.C.; Bonham T.; Safety and tolerability of intravenous valproic acid in healthy subjects: A phase I dose-escalation trial. Clin Pharmacokinet 2018,57(2),209-219 [DOI: 10.1007/s40262-017-0553-1]
  81. Muthaffar O.Y.; Almahmudi S.M.; Alrabghi M.O.; Bin Mahfouz M.M.; Alfawaz N.S.; Valproic acid for children below 2 years of age with epilepsy. Neurosciences 2021,26(4),357-365 [DOI: 10.17712/nsj.2021.4.20210075]
  82. Maan J.S.; Carbamazepine 2019
  83. Kabi A.; Kaeley N.; Bhatia R.; Mohanty A.; Carbamazepine-induced hyponatremia – A wakeup call. J Family Med Prim Care 2019,8(5),1786-1788 [DOI: 10.4103/jfmpc.jfmpc_185_19]
  84. Lu X.; Wang X.; Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf 2017,16(1),77-87 [DOI: 10.1080/14740338.2017.1248399]
  85. Gupta M.; Tripp J.; Phenytoin 2022
  86. Uribe-San-Martín R.; Ciampi E.; Uslar W.; Risk factors of early adverse drug reactions with phenytoin: A prospective inpatient cohort. Epilepsy Behav 2017,76,139-144 [DOI: 10.1016/j.yebeh.2017.08.032]
  87. Zoheir N.; Hughes F.J.; The management of drug-influenced gingival enlargement. Prim Dent J 2019,8(4),34-39 [DOI: 10.1308/205016820828463816]
  88. Karn M.; Sah R.; Sapkota S.; Phenytoin-induced gingival overgrowth. Cleve Clin J Med 2022,89(9),488-489 [DOI: 10.3949/ccjm.89a.21107]
  89. Basutkar R.S.; Indu T.H.; Hypersensitivity reaction associated with phenytoin. J Basic Clin Pharm 2015,6(4),119-121 [DOI: 10.4103/0976-0105.168054]
  90. Ghannam M.; Mansour S.; Nabulsi A.; Abdoh Q.; Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature. Clin Mol Allergy 2017,15(1),14 [DOI: 10.1186/s12948-017-0069-0]
  91. Nanau R.M.; Neuman M.G.; Adverse drug reactions induced by valproic acid. Clin Biochem 2013,46(15),1323-1338 [DOI: 10.1016/j.clinbiochem.2013.06.012]
  92. Guo H.L.; Jing X.; Sun J.Y.; Valproic acid and the liver injury in patients with epilepsy: An update. Curr Pharm Des 2019,25(3),343-351 [DOI: 10.2174/1381612825666190329145428]
  93. Hasegawa N.; Tohyama J.; Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy. Epilepsy Behav 2021,117,107515 [DOI: 10.1016/j.yebeh.2020.107515]
  94. Goji H.; Kanemoto K.; The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study. Seizure 2019,67,1-4 [DOI: 10.1016/j.seizure.2019.02.009]
  95. Specchio N.; Pietrafusa N.; Vigevano F.; Is cenobamate the breakthrough we have been wishing for? Int J Mol Sci 2021,22(17),9339 [DOI: 10.3390/ijms22179339]
  96. Roberti R.; De Caro C.; Iannone L.F.; Zaccara G.; Lattanzi S.; Russo E.; Pharmacology of cenobamate: Mechanism of action, pharmacokinetics, drug–drug interactions and tolerability. CNS Drugs 2021,35(6),609-618 [DOI: 10.1007/s40263-021-00819-8]
  97. Darpo B.; Sager P.T.; Xue H.; Kamin M.; A phase 1 clinical study evaluating the effects of cenobamate on the QT interval. Clin Pharmacol Drug Dev 2022,11(4),523-534 [DOI: 10.1002/cpdd.1077]
  98. Howard P.; Remi J.; Remi C.; Levetiracetam. J Pain Symptom Manage 2018,56(4),645-649 [DOI: 10.1016/j.jpainsymman.2018.07.012]
  99. Steinhoff B.J.; Klein P.; Klitgaard H.; Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy Behav 2021,118,107939 [DOI: 10.1016/j.yebeh.2021.107939]
  100. Meng J.; Yan Z.; Tao X.; The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: A meta‐analysis from randomized controlled trials. Epilepsia Open 2023,8(1),90-99 [DOI: 10.1002/epi4.12669]
  101. Kim H.; Kim D.W.; Lee S.T.; Antiepileptic drug selection according to seizure type in adult patients with epilepsy. J Clin Neurol 2020,16(4),547-555 [DOI: 10.3988/jcn.2020.16.4.547]
  102. Scheffer I.E.; Berkovic S.; Capovilla G.; ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017,58(4),512-521 [DOI: 10.1111/epi.13709]
  103. Fisher R.S.; Cross J.H.; D’Souza C.; Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017,58(4),531-542 [DOI: 10.1111/epi.13671]
  104. Liman M.N.P.; Al Sawaf A.; Epilepsy EEG StatPearls 2022
  105. Duncan J.S.; Brain imaging in epilepsy. Pract Neurol 2019,19(5),438-443 [DOI: 10.1136/practneurol-2018-002180]
  106. Santulli L.; Coppola A.; Balestrini S.; Striano S.; The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacol Res 2016,107,211-219 [DOI: 10.1016/j.phrs.2016.03.016]
  107. Kanner A.M.; Ashman E.; Gloss D.; Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy. Epilepsy Curr 2018,18(4),260-268 [DOI: 10.5698/1535-7597.18.4.260]
  108. Marson A.; Burnside G.; Appleton R.; The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: An open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021,397(10282),1363-1374 [DOI: 10.1016/S0140-6736(21)00247-6]
  109. Celdran de Castro A.; Nascimento F.A.; Beltran-Corbellini Á.; Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion. Seizure 2023,107,121-131 [DOI: 10.1016/j.seizure.2023.03.017]
  110. Brigo F.; Igwe S.C.; Lattanzi S.; Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2021,1(1),CD003032 [PMID: 33475151]
  111. Marson A.G.; Al-Kharusi A.M.; Alwaidh M.; The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007,369(9566),1016-1026 [DOI: 10.1016/S0140-6736(07)60461-9]
  112. Gaudio M.; Konstantara E.; Joy M.; van Vlymen J.; de Lusignan S.; Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study. BMC Pregnancy Childbirth 2022,22(1),73 [DOI: 10.1186/s12884-021-04351-x]
  113. Mari L.; Placidi F.; Romigi A.; Levetiracetam, lamotrigine and carbamazepine: Which monotherapy during pregnancy? Neurol Sci 2022,43(3),1993-2001 [DOI: 10.1007/s10072-021-05542-2]
  114. Park K.M.; Kim S.E.; Lee B.I.; Antiepileptic drug therapy in patients with drug-resistant epilepsy. J Epilepsy Res 2019,9(1),14-26 [DOI: 10.14581/jer.19002]
  115. National Institute for Health and Care Excellence In: Overview: Epilepsies in children, Young People and Adults NICE 2022
  116. Latimer D.; Le D.; Falgoust E.; Brivaracetam to treat partial onset seizures in adults. Health Psychol Res 2023,10(5),56782 [DOI: 10.52965/001c.56782]
  117. Kim J.H.; Kim D.W.; Lee S.K.; First add‐on perampanel for focal‐onset seizures: An open‐label, prospective study. Acta Neurol Scand 2020,141(2),132-140 [DOI: 10.1111/ane.13197]
  118. Singh A.; Cenobamate for treatment-resistant focal seizures: Current evidence and place in therapy. J Cent Nerv Syst Dis 2022,14 [DOI: 10.1177/11795735211070209]
  119. Buckley C.T.; Waters O.R.; DeMaagd G.; Cenobamate: A new adjunctive agent for drug-resistant focal onset epilepsy. Ann Pharmacother 2021,55(3),318-329 [DOI: 10.1177/1060028020941113]
  120. Kwan P.; Arzimanoglou A.; Berg A.T.; Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010,51(6),1069-1077 [DOI: 10.1111/j.1528-1167.2009.02397.x]
  121. French J.A.; Kanner A.M.; Bautista J.; Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004,62(8),1252-1260 [DOI: 10.1212/01.WNL.0000123693.82339.FC]
  122. French J.A.; Kanner A.M.; Bautista J.; Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004,62(8),1261-1273 [DOI: 10.1212/01.WNL.0000123695.22623.32]
  123. Patsalos P.N.; Spencer E.P.; Berry D.J.; Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 2018,40(5),526-548 [DOI: 10.1097/FTD.0000000000000546]
  124. Jacob S.; Nair A.B.; An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R D 2016,16(4),303-316 [DOI: 10.1007/s40268-016-0148-6]
  125. Schultz L.; Mahmoud S.H.; Is therapeutic drug monitoring of lacosamide needed in patients with seizures and epilepsy? Eur J Drug Metab Pharmacokinet 2020,45(3),315-349 [DOI: 10.1007/s13318-019-00601-8]
  126. Yamamoto Y.; Usui N.; Nishida T.; Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs. Ther Drug Monit 2017,39(4),446-449 [DOI: 10.1097/FTD.0000000000000416]
  127. St E.K.; Frey L.C.; Britton J.W.; Frey L.C.; Hopp J.L.; Electroencephalography (EEG): An Introductory Text and Atlas of Normal and Abnormal Findings in Adults, Children, and Infants 2016
  128. Rusli R.A.; Makmor Bakry M.; Mohamed Shah N.; Hui Jan T.; Seizure severity assessment tools for adult epilepsy patients: A systematic review. Epilepsy Behav 2023,142,109154 [DOI: 10.1016/j.yebeh.2023.109154]
  129. Vélez-Ruiz N.J.; Pennell P.B.; Issues for women with epilepsy. Neurol Clin ix.2016,34(2),411-425 [DOI: 10.1016/j.ncl.2015.11.009]
  130. Meadow S.R.; Anticonvulsant drugs and congenital abnormalities. Lancet 1968,292(7581),1296 [DOI: 10.1016/S0140-6736(68)91781-9]
  131. Tomson T.; Battino D.; Bonizzoni E.; Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. Lancet Neurol 2018,17(6),530-538 [DOI: 10.1016/S1474-4422(18)30107-8]
  132. Christensen J.; Trabjerg B.B.; Sun Y.; Prenatal exposure to valproate and risk of congenital malformations—Could we have known earlier?—A population‐based cohort study. Epilepsia 2021,62(12),2981-2993 [DOI: 10.1111/epi.17085]
  133. Veroniki A.A.; Cogo E.; Rios P.; Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 2017,15(1),95 [DOI: 10.1186/s12916-017-0845-1]
  134. Smith M.L.; Neuropsychology in epilepsy: Children are not small adults. Epilepsia 2010,51(S1),68-69 [DOI: 10.1111/j.1528-1167.2009.02451.x]
  135. Wilmshurst J.M.; Berg A.T.; Lagae L.; Newton C.R.; Cross J.H.; The challenges and innovations for therapy in children with epilepsy. Nat Rev Neurol 2014,10(5),249-260 [DOI: 10.1038/nrneurol.2014.58]
  136. Knupp K.; Koh S.; Park K.; Pediatric epilepsy: Five new things. Neurol Clin Pract 2012,2(1),40-47 [DOI: 10.1212/CPJ.0b013e31824c6cbd]
  137. Minardi C.; Minacapelli R.; Valastro P.; Epilepsy in children: from diagnosis to treatment with focus on emergency. J Clin Med 2019,8(1),39 [DOI: 10.3390/jcm8010039]
  138. Kim E.H.; Ko T.S.; Cognitive impairment in childhood onset epilepsy: Up-to-date information about its causes. Korean J Pediatr 2016,59(4),155-164 [DOI: 10.3345/kjp.2016.59.4.155]
  139. Song J.M.; Hahn J.; Kim S.H.; Chang M.J.; Efficacy of treatments for infantile spasms: A systematic review. Clin Neuropharmacol 2017,40(2),63-84 [DOI: 10.1097/WNF.0000000000000200]
  140. Wheless J.W.; Gibson P.A.; Rosbeck K.L.; Infantile spasms (West syndrome): Update and resources for pediatricians and providers to share with parents. BMC Pediatr 2012,12(1),108 [DOI: 10.1186/1471-2431-12-108]
  141. Wilmshurst J.M.; Gaillard W.D.; Vinayan K.P.; Summary of recommendations for the management of infantile seizures: Task F orce R eport for the ILAE C ommission of P ediatrics. Epilepsia 2015,56(8),1185-1197 [DOI: 10.1111/epi.13057]
  142. Hancock E.C.; Osborne J.P.; Edwards S.W.; Treatment of infantile spasms. Cochrane Database Syst Rev 2013(6),CD001770 [PMID: 23740534]
  143. O’Callaghan F.J.K.; Edwards S.W.; Alber F.D.; Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): A randomised, multicentre, open-label trial. Lancet Neurol 2017,16(1),33-42 [DOI: 10.1016/S1474-4422(16)30294-0]
  144. Anwar A.; Saleem S.; Patel U.K.; Arumaithurai K.; Malik P.; Dravet syndrome: An overview. Cureus 2019,11(6),e5006 [PMID: 31497436]
  145. Millichap J.J.; Koh S.; Laux L.C.; Nordli D.R.; Child Neurology: Dravet syndrome: When to suspect the diagnosis. Neurology 2009,73(13),e59-e62 [DOI: 10.1212/WNL.0b013e3181b9c880]
  146. Strzelczyk A.; Schubert-Bast S.; A practical guide to the treatment of Dravet syndrome with anti-seizure medication. CNS Drugs 2022,36(3),217-237 [DOI: 10.1007/s40263-022-00898-1]
  147. Wirrell E.C.; Nabbout R.; Recent advances in the drug treatment of Dravet syndrome. CNS Drugs 2019,33(9),867-881 [DOI: 10.1007/s40263-019-00666-8]
  148. Amrutkar C.; Riel-Romero R.M.; Lennox Gastaut Syndrome 2022
  149. Knupp K.G.; Scheffer I.E.; Ceulemans B.; Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol 2022,79(6),554-564 [DOI: 10.1001/jamaneurol.2022.0829]
  150. Cross J.H.; Auvin S.; Falip M.; Striano P.; Arzimanoglou A.; Expert opinion on the management of Lennox–Gastaut syndrome: Treatment algorithms and practical considerations. Front Neurol 2017,8,505 [DOI: 10.3389/fneur.2017.00505]
  151. Brigo F.; Jones K.; Eltze C.; Matricardi S.; Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2021,4(4),CD003277 [PMID: 33825230]
  152. Rosati A.; De Masi S.; Guerrini R.; Antiepileptic drug treatment in children with epilepsy. CNS Drugs 2015,29(10),847-863 [DOI: 10.1007/s40263-015-0281-8]
  153. Mohd-Tahir N.A.; Li S.C.; Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children. Epilepsy Res 2018,139,113-122 [DOI: 10.1016/j.eplepsyres.2017.11.007]
  154. Visa-Reñé N.; Raspall-Chaure M.; Paredes-Carmona F.; Coromina J.S.; Macaya-Ruiz A.; Clinical experience with brivaracetam in a series of 46 children. Epilepsy Behav 2020,107,107067 [DOI: 10.1016/j.yebeh.2020.107067]
  155. Farkas M.K.; Kang H.; Fogarasi A.; Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial. Epilepsia 2022,63(4),855-864 [DOI: 10.1111/epi.17187]
  156. Mintz M.; Pina-Garza J.E.; Wolf S.M.; Safety and tolerability of adjunctive Eslicarbazepine acetate in pediatric patients (aged 4-17 years) with focal seizures. J Child Neurol 2020,35(4),265-273 [DOI: 10.1177/0883073819890997]
  157. Moavero R.; Pisani L.R.; Pisani F.; Curatolo P.; Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 2018,17(10),1015-1028 [DOI: 10.1080/14740338.2018.1518427]
  158. Ortiz de la Rosa J.S.; Ladino L.D.; Rodríguez P.J.; Rueda M.C.; Polanía J.P.; Castañeda A.C.; Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure 2018,56,34-40 [DOI: 10.1016/j.seizure.2018.01.014]
  159. Driessen J.T.; Wammes-van der Heijden E.A.; Verschuure P.; Fasen K.C.F.M.; Teunissen M.W.A.; Majoie H.J.M.; Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy. Epilepsy Behav Rep 2023,21,100574 [DOI: 10.1016/j.ebr.2022.100574]
  160. Kirkham F.; Auvin S.; Moreira J.; Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial. Epilepsy Behav 2020,105,106962 [DOI: 10.1016/j.yebeh.2020.106962]
  161. Ferreira J.A.; Le Pichon J.B.; Abdelmoity A.T.; Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures – An open-label trial. Seizure 2019,71,166-173 [DOI: 10.1016/j.seizure.2019.05.016]

MeSH Term

Humans
Anticonvulsants
Epilepsy
Seizures
Drug Interactions

Chemicals

Anticonvulsants
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0ASMsepilepsyseizuresdifferentEpilepsyconditionseveralcasesmayanti-seizuremedicationstreatmentaimsagedruginteractionsreviewchronicneurologicalcharacterizedunprovokedrecurrenttypescausecanvarygeneticcomponentotherscausedbraininjuriesinfectionsunderlyingconditionsTreatmenttypicallyinvolvesalthoughapproachessurgeryspecialdietconsideredspecificeffectivelymanagepotentiallyeliminateminimizingaccompanyingsideeffectsManyavailablechoicemedicationdependsfactorsincludingtypepatient'sgeneralhealthpotentialsignificantadvancementsrecentdecadesledapprovalmanyNewerofferbroaderrangemechanismsactionimprovedtolerabilityprofilesreducedcomparedolderdrugsdiscusspharmacologicalcharacteristicsclinicalapplicationseffectivenesssafetyparticularemphasisvariousgroupsespeciallychildrenMoreoverseeksprovidecomprehensiveunderstandingASMtherapymanagementassistingphysiciansselectingsuitablepatientsAnti-seizureMedications:ChallengesOpportunitiesneuropharmacologypharmacotherapyprecisionmedicine

Similar Articles

Cited By